ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.10−0.05 (-4.35%)
Close on Nov 18, 2026Market cap $115.90MP/E –Yield –
ProQR Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
ProQR Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -€49.01M. For fiscal 2025 it was -€52.79M. The highest annual figure on record is €21.55M in fiscal 2023.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€52.79M | – |
| FY2024 | Dec 31, 2024 | -€36.39M | -268.9% |
| FY2023 | Dec 31, 2023 | €21.55M | – |
| FY2022 | Dec 31, 2022 | -€68.51M | – |
| FY2021 | Dec 31, 2021 | -€26.01M | – |
| FY2020 | Dec 31, 2020 | -€47.06M | – |
| FY2019 | Dec 31, 2019 | -€43.97M | – |
| FY2018 | Dec 31, 2018 | -€28.49M | – |
| FY2017 | Dec 31, 2017 | -€34.95M | – |
| FY2016 | Dec 31, 2016 | -€34.22M | – |
| FY2015 | Dec 31, 2015 | -€24.23M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€12.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -€11.15M | – |
| Q4 FY2025 | Dec 31, 2025 | -€13.36M | – |
| Q3 FY2025 | Sep 30, 2025 | -€12.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -€11.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -€15.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -€9.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -€5.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -€6.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -€15.13M | -133.8% |
| Q4 FY2023 | Dec 31, 2023 | -€5.32M | – |
| Q3 FY2023 | Sep 30, 2023 | -€7.51M | – |
| Q2 FY2023 | Jun 30, 2023 | -€10.35M | – |
| Q1 FY2023 | Mar 31, 2023 | €44.73M | – |
| Q4 FY2022 | Dec 31, 2022 | -€17.83M | -571.1% |
| Q3 FY2022 | Sep 30, 2022 | -€15.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -€14.84M | – |
| Q1 FY2022 | Mar 31, 2022 | -€20.47M | – |
| Q4 FY2021 | Dec 31, 2021 | €3.79M | – |
| Q3 FY2021 | Sep 30, 2021 | -€8.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -€9.98M | – |
| Q1 FY2021 | Mar 31, 2021 | -€11.76M | – |
| Q4 FY2020 | Dec 31, 2020 | -€11.76M | – |
| Q3 FY2020 | Sep 30, 2020 | -€9.81M | – |
| Q2 FY2020 | Jun 30, 2020 | -€10.49M | – |
| Q1 FY2020 | Mar 31, 2020 | -€15.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -€11.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -€8.77M | – |
| Q2 FY2019 | Jun 30, 2019 | -€10.88M | – |
| Q1 FY2019 | Mar 31, 2019 | -€12.36M | – |
| Q4 FY2018 | Dec 31, 2018 | -€9.10M | – |
| Q3 FY2018 | Sep 30, 2018 | -€4.26M | – |
| Q2 FY2018 | Jun 30, 2018 | -€5.42M | – |
| Q2 FY2017 | Jun 30, 2017 | -€9.85M | – |
See a number that looks wrong?